Le Lézard
Classified in: Science and technology, Covid-19 virus
Subject: MRR

Global GDPR Services Strategic Business Report 2023: Market Research and Compliance in the GDPR Era


DUBLIN, June 7, 2023 /PRNewswire/ -- The "GDPR Services: Global Strategic Business Report" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

Global GDPR Services Market to Reach $7.4 Billion by 2030

The global market for GDPR Services estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$7.4 Billion by 2030, growing at a CAGR of 17.7% over the analysis period 2022-2030.

Solutions, one of the segments analyzed in the report, is projected to record 16.9% CAGR and reach US$4.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 19% CAGR for the next 8-year period.

The U.S. Market is Estimated at $416.5 Million, While China is Forecast to Grow at 17.6% CAGR

The GDPR Services market in the U.S. is estimated at US$416.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$393.6 Million by the year 2030 trailing a CAGR of 17.6% over the analysis period 2022 to 2030.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.4% and 16.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR.

Looking Ahead to 2023

Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New for 2023?

Key Topics Covered:

MARKET OVERVIEW

MARKET TRENDS & DRIVERS

FOCUS ON SELECT PLAYERS (Total 102 Featured)

For more information about this report visit https://www.researchandmarkets.com/r/lyyjtk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 



SOURCE Research and Markets


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: